VEGF Antagonist Dosing Intervals for Lower AMD Injection Burden
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-VEGF treatments for ocular neovascular diseases, such as age-related macular degeneration, require frequent injections, which are burdensome for patients and caregivers, and carry risks like pain and intraocular pressure rise, with limited visual acuity gains in many patients.
Innovation Solution
Administer three initial doses of a VEGF antagonist at 4-week intervals, followed by additional doses every 8 or 12 weeks based on disease activity assessments using visual and anatomic criteria, allowing for flexible dosing regimens to optimize treatment frequency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If frequent injections of VEGF antagonist are administered, then treatment effectiveness is maintained, but patient burden and treatment complexity increase
Solution Approach 1:
The patent implements a dynamic dosing regimen where the frequency of VEGF antagonist injections is adjusted based on individual patient response and disease activity. After an initial loading phase of monthly injections, patients are assessed and transitioned to either every-8-weeks or every-12-weeks dosing based on their specific needs, optimizing both effectiveness and patient convenience
Solution Approach 2:
The treatment protocol employs periodic injection schedules with distinct phases: a loading phase with monthly injections followed by extended intervals of every 8 or 12 weeks. This periodic structure allows for initial rapid control followed by maintenance dosing, reducing overall treatment frequency while maintaining efficacy
2Reliability
If frequent injections are administered, then disease control is improved, but risk of adverse effects increases
Solution Approach 1:
The dosing frequency is dynamically adjusted based on disease activity assessment rather than following a fixed schedule. Patients who achieve stable control can transition to less frequent dosing, thereby reducing cumulative exposure to adverse effects while maintaining adequate disease control
Solution Approach 2:
The treatment protocol incorporates regular assessment of disease activity and patient response to determine subsequent dosing frequency. This feedback mechanism allows for optimization of treatment intensity, reducing dosing frequency when control is adequate and preventing unnecessary adverse effects from excessive dosing
3Device complexity
If fixed frequent dosing is used, then treatment simplicity is maintained, but visual acuity gains are limited
Solution Approach 1:
The patent implements individualized dosing intervals (every 8 weeks or every 12 weeks) based on patient-specific response to treatment rather than applying a uniform schedule to all patients. This dynamic approach optimizes visual acuity outcomes for each patient while maintaining clear guidance for clinicians
Solution Approach 2:
The treatment protocol varies the dosing interval parameter based on patient response criteria. By changing the time interval between injections according to assessed disease activity and visual response, the protocol optimizes therapeutic outcomes while maintaining straightforward administration guidelines
Data Source
AI summary
A method is provided for reducing the treatment burden for patients who have an intraocular neovascular disorder, the method comprising administering a therapeutically effective amount of VEGF antagonist on a dosing schedule that includes treatment intervals of 8 and/or 12 weeks.